- Aprea Therapeutics ( NASDAQ: APRE ) received formal notice from The Nasdaq Stock Market that it has regained compliance with its minimum bid price for continued listing on the Nasdaq Global Select Market.
- "We are excited about regaining compliance and we believe our recent financing, which was supported by quality institutions, has strengthened our balance sheet and enabled the Company to continue developing its clinical asset, ATRN-119, and its pre-clinical asset ATRN-W1051," President & CEO Oren Gilad, Ph.D. commented.
For further details see:
Aprea Therapeutics regains Nasdaq compliance with minimum bid price requirement